International Journal of Research, Innovation and Practice
Vol. 1, Issue 2, May 2026, Pp. 1-27
ISSN: 3139-3195
: https://doi.org/10.67497/ijrip.1.2.42
https://theglobalpublishers.org/journals/index.php/ijrip

Article

Reshaping the global pharmaceutical supply chain: challenges and opportunities in the wake of trade wars and geopolitical tensions

Dr. Kapil Dev Pandey
PhD, MIMA, PGDMM, PGDIBO, MBA, B. PHARM
kdpandey@gmail.com
ORCID: 0000-0002-8951-8855

Article History
Received: 28 April, 2026
Revised: 9 May, 2026
Accepted: 18 May, 2026
Published: 29 May, 2026

Abstract
The global pharmaceutical supply chain has undergone unprecedented transformation due to escalating trade wars and geopolitical tensions, fundamentally challenging the efficiency-driven globalization model that dominated the industry for decades. This study examines how these disruptions are reshaping pharmaceutical supply chains, with particular focus on India's strategic position as a major pharmaceutical manufacturing hub. This comprehensive analysis employs a mixed-methods approach, incorporating case study analysis, empirical evidence examination, and strategic framework assessment. The study utilizes the VUCA (Volatility, Uncertainty, Complexity, and Ambiguity) framework to understand supply chain challenges and examines regional rebalancing effects, particularly focusing on the "China + 1" strategy and its implications for global pharmaceutical manufacturing.

The research demonstrates that while trade wars create substantial immediate challenges, they simultaneously generate unprecedented opportunities for building more robust supply chain models. This has led to new forms of hybrid globalization-regionalization which involves global efficiency coupled with regional resilience achieved by clever localization mechanisms. The solutions that involve the use of technology, such as the advanced analytics and digital supply chains, give end-to-end visibility and allow one to monitor it real-time. The transition between single-source procurement strategy to multi-source procurement strategy constitutes a basic transformation to diversification of supply chains.

The transformation means a permanent shift to resilience-optimization instead of efficiency-maximization, not that it can be executed in a short period of time, but in the long-term persistence in the constant investment in capabilities and relations. This will require mastering the tasks of cost effectiveness and supply chain security and international collaboration which will make the pharmaceutical security a common agenda across boarders. The geopolities and related trade wars changed significantly the environment of the pharmaceutical supply chain, and it provided both challenges of an unprecedented order and exceptional opportunities. The industry's response will determine not only its future competitiveness but also its ability to ensure continued access to essential medications for patients worldwide.

Keywords: *Student Well-Being, Mental Wellness, Holistic Development, Higher Education*

1 INTRODUCTION AND BACKGROUND

The present-day global pharmaceutical supply chain can be seen as one of the most intertwined and interdependent structures of modern economy that is largely formed by years of globalization and optimization of international trade. At least a transcontinental web of relationships, between suppliers of raw materials on one continent and manufacturing plants on another continent, and distribution systems that serve markets on every continent, is involved. The pharmaceutical industry's evolution toward this globalized model has been

driven by the pursuit of cost efficiency, access to specialized capabilities, and the need to serve diverse international markets with life-saving medications.

This interdependence between the world has been enormous and extensive. Study of international trade patterns shows that in no region is it self-sufficient in all important classifications and that every region depends upon the trade of others to supply over one-fourth of at least one important kind of good. This interdependence is especially high within the pharmaceutical industry whereby the augmented dependence on global suppliers has been made one of the founding pillars of this line of industry, especially to cut costs and increase the competitive edge (Sabogal De La Pava & Tucker, 2023). Globalization of economies has helped pharmaceutical companies to obtain raw material, active pharmaceutical ingredients (APIs) as well as finished goods, across geopolitical boundaries thus lowering costs and increasing productivity.

The pharmaceutical supply chain's global nature comprises numerous stakeholders in disparate regions operating within different regulatory environments. This interconnectivity has helped in development of a strong and varied supply chain which supplies an array of markets in the regions of the globe as firms are able to take advantage of cost benefits of various regions and streamlining production techniques with the rise in demand in various markets. Nevertheless, this approach to globalization has established a framework through which destabilization in a single area, e.g. factory closures of China or India, can cause a major shortage of essential APIs worldwide (Sabogal De La Pava & Tucker, 2023).

The COVID-19 pandemic acted as such a breaking point and demonstrated to the world serious weaknesses in the globalized supply chains of manufacturing of pharmaceuticals and raised fundamental questions that the industry needs to consider about supply chain strategy. The crisis demonstrated how dependency on single geographic sources for essential drugs and medical supplies could lead to significant supply chain disruptions, with global trade restrictions, lockdowns, and surging demand causing widespread shortages and delays (Sabogal De La Pava & Tucker, 2023). This situation highlighted the urgent need for more diversified and resilient supply chains to mitigate risks and ensure reliable distribution of critical healthcare resources.

The pandemic's impact was particularly severe, with the disruptions caused by the pandemic having a moderating effect on growth trends, though it was expected to return to familiar patterns by 2024 (Miebach Consulting, 2024). The COVID-19 pandemic has also put pharmaceutical supply chains through an exceptionally severe stress test, giving forward-thinking businesses a chance to evaluate how they can improve capacity across the board, from patient delivery to manufacturing (Sabogal De La Pava & Tucker, 2023).

Rising geopolitical tensions have created another layer of complexity for pharmaceutical supply chains. Emerging geopolitical risks have begun to threaten global supply chains, including those that produce life-saving drugs, with export bans potentially preventing companies from shipping products internationally (Sabogal De La Pava & Tucker, 2023). These geopolitical tensions create uncertainty and can severely impact company strategies and supply chain stability.

Key geopolitical hotspots further exacerbate supply chain instability. Recently, several countries have banned or threatened to ban the export of drugs in short supply, including India, France, Poland, Greece, Norway, Spain, and Bulgaria (Sabogal De La Pava & Tucker, 2023). Export bans imposed by certain countries can hinder pharmaceutical companies' ability to distribute their products internationally, potentially leading to shortages and disruptions in global drug availability.

The current environment is further complicated by renewed inflation pressures. Around the world, rising inflation is having a significant impact on the pharmaceutical industry, with the majority of pharmaceutical companies seeing high costs for raw materials and expecting a decline in profit margins (GEP, 2022). Reasons for the steep increase in

ISSN: 3139-3195

inflation include high energy and food costs, along with supply chain constraints, with the Russia-Ukraine war and the subsequent rise in energy prices driving up the prices of almost all commodities.

(Rathore et al., 2023) observed that in the pharmaceutical industry, the primary drivers of competitiveness are substitute products and rivalry among competitors, while supplier power and new entrants have limited impact. The study suggested product differentiation, strong marketing and customer relationship building to strengthen market position. Lean supply chain management brings tremendous improvement in supply chain performance and organisational productivity in manufacturing sector (Chaturvedi et al., 2021). Together these studies show that competitiveness and productivity are dependent on strategic management, innovation and operational efficiency.

The pharmaceutical industry in Europe has been particularly affected, with significant concerns around the cost for manufacturing drugs due to high inflation rates of over 7% throughout Europe (GEP, 2022). There has been an increase of 30%-65% in energy prices, about 500% increase in logistics, as well as an increase of 50%-160% in the input cost of raw materials.

Climate change represents an additional layer of complexity, with extreme weather events becoming more frequent and severe. Pharmaceutical supply chains are extremely vulnerable to the effects of climate change and face many challenges from sourcing to distribution (Pharmaceutical Technology, 2023). Whether it's soaring temperatures, extreme cold snaps, or devastating floods, pharmaceutical logistics providers must ensure that shipments reach their destination in their intended condition without defect or delay.

Climate change has a direct impact on population health and in turn pharmaceutical demand. Wildfires, floods, landslides, and drought, often in places unused to such extreme weather events, are causing a global shift in public health issues and can quickly lead to a humanitarian crisis (Pharmaceutical Technology, 2023). Floods can quickly lead to an outbreak of waterborne diseases, and rising temperatures can increase the spread of mosquito-borne illnesses such as malaria.

The combination of dependencies in the context of globalization, the destabilization of supply chains generated by the pandemic, geopolitical risks, inflationary factors, and the effects of climate change, have presented the pharmaceutical supply chain with an operating environment it has never experienced. The problem is that the industry has to preserve the advantages of global integration as it creates resiliency against a growing complexity of risks and uncertainties.

The pharmaceutical supply chain has started to work in an environment that has Volatility Uncertainty Complexity, and Ambiguity (VUCA). Originally developed by the U.S. military to describe challenges faced in rapidly changing environments, the VUCA model has become increasingly relevant to pharmaceutical supply chain management. In this context, volatility refers to sudden changes in supply and demand, uncertainty reflects the unpredictability of these changes, complexity highlights the interconnected nature of global supply chains, and ambiguity points to the difficulty of interpreting incomplete or conflicting information (Sinceritas, 2024).

This VUCA environment has been intensified by several major disruptions that have fundamentally altered the operating landscape for pharmaceutical companies. Volatility in the life sciences industry refers to the speed of change, for example in regulations, innovations, market trends and changing suppliers or employees (Sinceritas, 2024). Supply chain volatility can be regulated through advanced solutions such as digital twins, which allow possible future scenarios to be visualized and the company's respective key figures to be included.

ISSN: 3139-3195

2 DIRECT ECONOMIC IMPACTS OF TRADE WARS ON PHARMACEUTICAL SUPPLY CHAINS

India's pharmaceutical industry stands as a cornerstone of the global healthcare supply chain, representing approximately 20% of global generic drug production by volume and serving over 200 countries worldwide. The sector encompasses more than 10,000 manufacturing facilities distributed across key pharmaceutical hubs including Maharashtra, Gujarat, Andhra Pradesh, and Karnataka. These facilities support over 3,000 pharmaceutical companies ranging from large multinational corporations to specialized generic manufacturers, creating a diverse ecosystem that contributes significantly to India's export economy.

The industry's manufacturing infrastructure includes 650 USFDA-compliant pharmaceutical plants, representing the highest concentration outside the United States. This regulatory compliance provides Indian manufacturers with direct access to the world's largest pharmaceutical market, where generic drugs account for approximately 90% of prescriptions filled. The sector's technological capabilities span the entire pharmaceutical value chain, from basic chemical synthesis to complex biotechnology products, including vaccines, biosimilars, and specialty pharmaceuticals.

India's pharmaceutical exports reached $25.4 billion in fiscal year 2023-24, with the United States representing the largest single market at approximately $9 billion in annual exports. It is also very important to note that the European Union in totality is another important market with Germany, United Kingdom and France being among the main destinations. Other growth opportunities lie in emerging markets in Africa, Latin America and Southeast Asia where pharmaceutical companies in India are putting greater emphasis in expanding their markets.

The Indian pharmaceutical industry's economic structure reveals significant dependencies that create vulnerabilities during trade wars. Another dependency critical supply chain reliance in the drug manufacture in India is that it is reliant on China in meeting around 70percent of active pharmaceutical ingredients (APIs). This has a billion dollar worth of supplying and importing form China most of the ingredients needed in manufacturing drugs that are relied upon by Indian companies. This reliance is not only in simple chemicals but also in complex intermediates used in manufacturing pharmaceuticals such as antibiotics, vitamins and special chemicals.

This dependency is especially acute when it comes to affecting trade in the economy. The cost benefits of Chinese API suppliers are 20-30% lower than of alternative sources, which makes diversification of immediate suppliers economically difficult. The Indian drug makers have developed their costs based on these supply relationships and many generic drug manufactures have profit margins of 15-20 percent which are based on low-cost Chinese materials.

In addition to APIs, India also imports a lot of pharmaceutical machines and packagings, and other pieces of special equipment from China. The pharmaceutical manufacturing equipment including sensors, controllers and monitoring systems used are made of electronics components mainly Asian based with most of them of Chinese origin. This introduces second-order dependencies which aggravate the economic effect of trade disruptions beyond the direct API supply chains.

The imposition of tariffs creates measurable economic impacts across multiple dimensions of India's pharmaceutical supply chain. Having done a detailed analysis of the possible scenarios of tariffs, the following are the economic implications of the exercise:

ISSN: 3139-3195

Table 1 - Tariff Impacts

Tariff Scenario	Estimated Annual Impact	Affected Export Value	Margin Impact
25% US Pharmaceutical Tariffs	$2.25 billion revenue at risk	$9 billion US exports	3-5% margin compression
10% Generalized Tariff	$850 million additional costs	$8.5 billion total exports	2-3% margin impact
China API Tariff (15%)	$450 million increased input costs	$3 billion API imports	1-2% cost increase

The market exposure and product line-up expose Indian pharmaceutical companies to differentiated effects. Companies with significant US market presence, including Sun Pharmaceutical, Dr. Reddy's Laboratories, and Cipla, face the highest revenue risks from potential tariff impositions. The firms circumstantially get about 40-50 percent of their revenues in US markets, a factor that renders them especially exposed to changes of trade policies.

The generic drugs producer faces the worst margin operation because it is positioned in the market as a price sensitive company. Over the last five years, the price of generic drugs in the US market has been decreasing at an average rate of 13% per year and there is not much that companies can do to include the extra costs of tariffs. The specialty drug sellers as well as the companies that are specialized in complex generics have the higher margins hence they serve as some source of resilience as far as the tariff effects are concerned.

Trade wars create cascading cost increases throughout India's pharmaceutical supply chain. The main effect is felt in the aspect of rising API prices, wherein, the Chinese vendors have to deal with retaliatory tariffs which get partly transferred to the Indian consumers. Secondary effects are the rising prices of pharmaceutical packaging material with an 8-12 percent rise in the prices of aluminum foil, plastic containers and especially specialized packing equipment attendant on periods of intense trade tension.

The prices of manufacturing machinery are also very expensive during a trade war with pharmaceutical machinery being imported mainly in China and Germany with enhanced duties. The cost of building new facilities increases by 15-20 percent as businesses attempt to set up production capacities in new areas. The cost of quality control and regulatory compliance due to vetting of new suppliers and operating in a variety of jurisdictions with differences in regulatory requirements add to the costs of doing business.

Pharmaceutical products shipping costs are also very volatile under situations of trade wars. Pharmaceutical export economics was directly affected in terms of container shipping costs of sending an export to the United States 150-200 percent during peak COVID-19 times, trade war. Economics of specialty drug exports: The cost of air shipping of temperature-sensitive pharmaceutical products rose between 80 % and 120 %.

Home country logistics expenses in India are also rising with firms diversifying the sources of their suppliers and or setting up alternative sources of supply. The increase in warehouse and delivery charges is because the companies have more inventory as a buffer in case of disruption of the supply chain. Temperature-Sensitive goods are placed in cold chains that involve extra investment in the redundant systems and alternate transportation networks.

Trade wars create significant currency volatility that directly impacts the economics of India's pharmaceutical exports. The Indian rupee's exchange rate against the US dollar experiences increased volatility during trade tension periods, with daily fluctuations of 1-2% becoming common compared to normal volatility of 0.5-0.8%. Such volatility incurs a

ISSN: 3139-3195

cost on the pharmaceutical firms involved in hedging activities, which in general amounts to 0.5-1.5 percent of the export earnings.

The Indian pharmaceutical exporters have some natural hedge based on currency due to depreciating rupee which makes the Indian pharmaceuticals more affordable in the dollar-denominated markets. Such advantage is partly countered by the higher prices of foreign API and basic materials, the bulk of which are quoted in US dollars. The net effect of this is affected differently by the firm depending on their individual cost structure and hedging strategies.

The volatility in Indian pharmaceutical stocks is found to be higher in the case of trade wars where the 20-30 percent volatility in the sector compared to other market days. This volatility affects companies' ability to raise capital for expansion and research and development investments. The release of shares by pharmaceutical companies which are either initial or published intelligence properties encounter timing issues and pricing pressure in the times of intense trade tensions.

Foreign direct investment in India's pharmaceutical sector shows mixed patterns during trade wars. Whereas other global companies continue to invest more in India as they diversify their supply chains, others put on huge investment decisions pending because of rising uncertainty. Whether the net effect on investment in the industry is positive or negative, depends on the type and the length of trade tensions.

The prolonged existence of trade wars is most catastrophic to generic drug companies in the market because they are sensitive to the price aspect hence their pricing strategy is influenced by the high volume, low margin business strategy. Such companies have normal gross and net margins of 50-60 percent and 8-12 percent respectively which offer no much space to cover extra expenses. The economic effect is realized as the decrease in the profitability instead of the lost sales because generic drugs are necessities, and substitution is not the probable alternative.

The firms that focus on complex generic and biosimilars have better sturdiness because of increased margins and a few competitors. Such products usually attract high prices which offer certain cushion in case there are high prices. However, the extended development cycle and tighter regulatory challenges of these products impose disparate weaknesses in matters pertaining to supply chain disturbances and regulatory slowdowns.

Indian API manufacturers are having variable effects on trade wars on them financially. In the case of companies manufacturing APIs in direct competition with Chinese exporters, the trade tensions are beneficial since they make Chinese suppliers less competitive. Nevertheless, there are also some complicating economic forces, owing to the fact that the same firms are involved in importation of raw materials and other intermediates which are produced in china.

The API industry has high capital expenditure involved in the establishment of new manufacturing capability, and the standard investments needed in the facility are 50-200 million dollars reliant on the level of the products. These investment demands are fueled by trade wars as businesses are struggling to decouple supply chains, resulting in opportunities and economic stresses on API makers.

The Indian pharmaceutical players are also putting a lot of money in the diversification of their supply chain in order to be less dependent on Chinese merchants. These investments entail qualifying new suppliers, making alternative sourcing arrangements, and building strategic inventory buffers. The total investment needed in an end-to-end diversification of a supply chain would be around 2-3 billion dollars in the Indian pharmaceutical sector over 5 years.

Qualification of new suppliers is both time and resource-intensive taking on average 18-36 months to qualification of complex APIs. Organizations will need to make investments to develop extended quality assurance systems, compliance with standards systems, and supply chains capabilities with a view to accommodate diversified supplier networks. Such

ISSN: 3139-3195

investments provide short term cost influences and long-term resilience advantages.

Trade warfare is why more investment in local API manufacturing capacity is occurring in India. The government's Production Linked Incentive (PLI) scheme for pharmaceuticals provides financial incentives for companies to establish domestic manufacturing capabilities for critical APIs. This represents a fundamental shift in the industry's cost structure, as domestic API production typically costs 15-25% more than Chinese imports.

This capacity increase has economic impacts at the levels beyond the direct costs incurred in manufacturing business which also contemplates development of infrastructure, skilled work force building and investments in technology transfer. There have been the development of integrated manufacturing sites where API production is done and the finished dosage form made at the same site. These help to generate some economies of scale thus compensating the increased cost of inputs partly.

The pharma companies of India have gained considerable market shares in the US market where there is lesser competition of the Chinese due to the trade tensions. When the trade war was on full swing, generic drug approvals by Indian companies rose by a quarter. This increase of market share is long-term business potential that is not dependent on the current state of the trade war.

European Union market also has more growth opportunities since the European firms are considering diversifying their supply chains to relocate their suppliers out of China. To exploit these opportunities, Indian pharmaceuticals are investing in regulatory compliance and the building of markets in Europe. Indian companies have a total market expansion value of between 3 to 5 billion dollars in the next five years.

Technology transfer and innovation partnerships are seen as the result of trade wars where the international big pharma firms want to develop their manufacturing potential in India. Through these alliances, the Indian firms get access to high-tech manufacturing techniques, product development solutions, as well as distribution channels across the world. These technology transfers have been estimated to contribute between 500 million and 1 billion dollars to the economy on annual basis.

Indian pharma firms are spending more on research and need to develop proprietary products by investing on it to decrease generic manufacturing, and it is aimed at making Indian pharma firms to be self reliant in terms of commercialisation. Further economic incentive to such investments is imposed through government incentives and tax benefits to R&D in the pharmaceutical industry. The long-term economic impact of increased innovation capabilities could transform the industry's value proposition and profitability profile.

This detailed analysis demonstrates that while trade wars create significant short-term economic pressures for India's pharmaceutical supply chains, they also generate strategic opportunities for market expansion, supply chain resilience, and technological advancement. The industry's ability to navigate these challenges while capitalizing on emerging opportunities will determine its long-term economic success in an increasingly complex global trade environment.

3 SUPPLY CHAIN DISRUPTION MECHANISMS

Pharmaceutical production in the modern-day is conducted with the use of complex global supply chains that are global in their structure and involve stakeholders on numerous continents within various regulatory markets. Once the tensions in trade intensify, these multilateral networks are exposed to a series of unprecedented disturbances that perrotate across all stages of new production, ranging between the extraction of raw materials and to the drug delivery end. The pharmaceutical industry's reliance on just-in-time manufacturing and single-source suppliers creates particular vulnerabilities that can rapidly translate into critical shortages affecting patient care worldwide.

ISSN: 3139-3195

The process of pharmaceutical supply chain is by far one of the most complicated systems of production in the contemporary economy. China supplies over 80% of the United States' generic drugs and approximately 40% of all active pharmaceutical ingredients (APIs) used in American medications (V Care International, 2024). Such concentration forms a dangerous dependence where the disturbances in one of the geographic areas may lead to the global lack of critical medications.

The interconnected nature of these supply chains means that even suppliers who appear geographically diversified often maintain hidden dependencies. Approximately 80% of India's pharmaceutical ingredients originate from Chinese suppliers, creating layered vulnerabilities where sourcing from India still means relying on China for critical components (Drug Discovery News, 2025). This creates cascading risks where a disruption in one country doesn't just affect direct trading partners but ripples through entire regional supply networks.

The sourcing of active pharmaceutical ingredients represents the most critical vulnerability in pharmaceutical supply chains during trade tensions. These essential building blocks of medications face multiple disruption mechanisms that can rapidly compromise drug availability. Export bans imposed by certain countries can hinder pharmaceutical companies' ability to distribute their products internationally, potentially leading to shortages and disruptions in global drug availability (SG Analytics, 2025).

Manufacturing lead times for specialized medications have increased dramatically during periods of trade tension, extending from an average of 90 days to 140 days, resulting in critical gaps in treatment availability (LinkedIn, 2025). This extension represents more than a 50% increase in production timelines, forcing pharmaceutical companies to fundamentally restructure their inventory management and production planning processes.

The scarcity of APIs has become particularly acute as many U.S. pharmaceutical companies depend on international partners, particularly in Asia, for the production of these essential components. Trade restrictions, tariffs, and raw material shortages in supplier countries lead to widespread API scarcities, causing drug manufacturers to grapple with production delays, limited batch runs, and stalled timelines for both new and existing treatments (SuperStaff, 2025).

Even when pharmaceutical supplies remain available, getting them across international borders has become increasingly complex during trade tensions. Customs procedures have become more intricate, with new documentation requirements and shifting compliance standards introduced in response to trade conflicts. These regulatory barriers are causing significant hold-ups at borders and ports, with shipments that once moved seamlessly through global transit networks now facing extended clearance times (SuperStaff, 2025).

The complexity of customs barriers creates major bottlenecks in pharmaceutical production, with documentation requirements becoming increasingly burdensome and time-consuming. These complications particularly affect complex treatments like biologics and vaccines, where precise timing is crucial for temperature-controlled supply chains (LinkedIn, 2025). The pharmaceutical industry's just-in-time inventory systems struggle to adjust to these longer timelines, forcing companies to rethink their entire supply chain strategies.

Regulatory compliance has become a moving target as trade policies evolve rapidly. Companies must navigate multiple jurisdictions with varying standards, creating additional layers of complexity that slow production and increase costs. The inconsistency in regulatory requirements disrupts supply chains and hinders demand planning and pharmacy-level distribution, creating inventory imbalances and gaps in regional drug availability.

The pharmaceutical enterprises are subjected to the fast conduction of verifying new suppliers due to trade tensions, which can cause quality control previoiusly unknown to the industry. Relocation of

ISSN: 3139-3195

production to new firms is a matter of concern as to how they are going to sustain the same quality of all the drugs produced with new producers lacking the knowledge, rigid procedures and strong infrastructure to manufacture pharmaceuticals (V Care International, 2024). This poses safety issues and possible recalls, which compromise the safety of the patients and reduces trust in the pharmaceutical supply chain.

The qualification process with the suppliers usually takes between 18 to 36 months especially with the complex APIs, which presents a huge delay when the companies have to switch suppliers because of trade barriers very rapidly. Firms are finding it quite difficult to sustain production, and at the same time to assure that the new suppliers will meet the high standards of quality that are demanded in the manufacture of pharmaceuticals during this qualification period. These timelines are usually shortened due to the urgency generated by issues of trade tensions, which can affect overall quality of quality assessments.

Quality control challenges extend beyond individual suppliers to encompass entire supply networks. When companies diversify their supplier base to reduce geographic concentration, they must establish quality control systems across multiple facilities and jurisdictions. This multiplication of quality oversight requirements strains resources and creates additional points of potential failure in the supply chain.

Trade tensions create multiple layers of cost increases throughout pharmaceutical supply chains, affecting both production economics and patient access. Tariffs raise the price of imported drugs, potentially impacting patient access and healthcare affordability, with this cost burden straining healthcare systems and creating disparities in treatment availability (Sensos, 2025). The economic pressures extend beyond direct tariff costs to include increased logistics, compliance, and inventory management expenses.

Recent data shows a 47% increase in drug shortages directly linked to supply chain issues, with critical medicines such as blood pressure medications, antibiotics, cancer treatments, and diabetes management drugs at significant risk of becoming unavailable (LinkedIn, 2025). These shortages create additional economic pressures as healthcare systems must source medications from alternative suppliers at premium prices or substitute with more expensive alternatives.

The pharmaceutical industry's response to cost pressures often involves passing increased expenses to healthcare systems, insurers, and ultimately patients. Generic drug manufacturers, which operate on slim profit margins, are particularly vulnerable to these cost increases and may be forced to reduce output or exit the market entirely, reducing competition and potentially driving further price inflation.

The uncertainty created by trade tensions fundamentally disrupts pharmaceutical companies' ability to maintain efficient inventory management and accurate demand planning. In traditional businesses, organizations are introducing additional inventory buffering and contingency action plans, all in the name of protecting patient access to essential medications in times of supply chain volatility (Drug Discovery News, 2025). This moving towards safety stock piling over the lean inventory management uses a great amount of working capital and rises unit cost of storing.

The highly developed just- in-time inventory systems will be incapable of handling the uncertainty of trade tensions. Business has to weigh the value of surplus carrying inventory against the risk of stockout costs that have the potential of compromising patient care. This balancing act is especially tough with regard to temperate-sensitive drugs, which require specialized storage facilities, and which have short shelf lives.

It is as meatballs as demand planning when supply chains are regularly disrupted exponentially increases the complexity of demand planning. Historical-based models of forecasting are not helpful when an event like the geopolitical situation could change the availability of supplies at any given moment. The scenario-based planning must be carried out by firms

ISSN: 3139-3195

and consider the different degrees of disruption in the supply chain with advanced modeling capacity and more planning resources.

The failure of supply chains ends up in the overstretched health system and patients compromised. Healthcare providers are faced with several tough choices concerning the treatment options in case vital medicines are unobtainable or too costly. The pharmaceutical environment of 2025 has experienced some of the worst cases of drug shortage ever witnessed and some vital drugs used in salient disorders and diseases causing mortality challenges have become hard to access.

Pharmaceutical supply chain failures have repercussions to healthcare systems. The hospitals and clinics should allocate more resources to get alternative medications, handle patient communiques regarding treatment changes, and coordinate with various suppliers to ensure that they have sufficient amounts of medications. Such operational burdens consume health care resources and distract health care professionals away toward direct patient care processes.

There is nothing that can underserve the psychological damage on the patients when their regular drugs are out of stock or they are changed frequently due to supply chain issues. The chronic patients who have reached a stable level on a particular treatment may face the drawback of treatment and find their conditions to reach new heights or may develop the complications, which could have been avoided had they had access to medication properly.

Comprehensive measures are being taken by pharmaceutical firms to develop the resilience of supply chain against the disturbances dispensed on supply chain due to trade tensions. The resilience and flexibility of the supply chain have proved to be a decisive competitive edge, and those firms that invested in traceability and supply chain mapping had shown a profound competitive edge in terms of anticipating tariff-related threats (Drug Discovery News, 2025). Such investments on the visibility and risk monitoring tools help firms to detect possible disruption in production in advance.

The industry is shifting towards wider supplier networks that will lessen the reliance on each geographical area as well as suppliers. Such diversification necessitates an intensive investment in qualifying suppliers and developing quality systems as well as supply chain management capabilities. They are also forming strategic alliances with suppliers in various parts of the world to ensure redundancy in supplying chains.

The adoption of technology is picking up pace with owners of companies aiming at enhancing supply chain visibility and responsiveness. Real-time monitoring systems, artificial intelligence, and advanced analytics are being implemented so that it is easier to predict and respond to supply chain disruption. Such technological solutions are useful in assisting companies in optimising the inventory levels of various products, finding the alternative suppliers, planning their logistics and complex logistics operations in various regions.

The shift in the pharmaceutical supply chain towards resilience-oriented instead of efficiency-oriented chain models constitutes the essential change in industry strategy. Although such a transition comes with great expenses and logistical complexity, it is necessary to maintain a steady supply to patients being fed with vital drugs in a geopolitically turbulent atmosphere. Those firms which manage to negotiate this metamorphosis will be in a better position to offer services to the patients as well as having a competitive edge in the emerging global pharmaceutical landscape.

4 REGIONAL REBALANCING EFFECTS: TRADE WAR IMPACTS ON PHARMACEUTICAL SUPPLY CHAIN GEOGRAPHY

Introduction of US tariffs in importation of goods from China has led to substantial geographical redistribution in global pharmaceutical supply chains, on which developing countries specially India have

ISSN: 3139-3195

both benefits and risks. This rebalancing represents one of the most substantial shifts in global pharmaceutical trade patterns since the industry's initial globalization in the 1990s.

The US pharmaceutical industry has undergone a drastic change in pattern of imports due to application of high tariffs on Chinese products. In April 2025, the United States addressed active pharmaceutical ingredients (APIs) that make up about 40 percent of U.S. generic drugs, imposed tariffs as high as 245 percent on Chinese imports, consisting of 125 percent reciprocal tariffs and 20 percent fentanyl-related fees, among others (European Pharmaceutical Review, 2025). This belligerent tariff regime has radically changed the economics of importing drugs into the country especially those of the Chinese origin.

The impact on Chinese pharmaceutical exports has been immediate and substantial. Chinese drug makers face squeezed profit margins as the United States presses ahead with tariffs on pharmaceuticals despite pledges to reduce domestic drug prices (Reuters, 2025). The implementation of these tariffs aims to bring manufacturing back to the US, even at the cost of higher drug prices, creating a direct contradiction with drug price reduction policies but aligning with broader strategic objectives of reducing dependence on Chinese supply chains.

The scale of potential trade diversion is substantial, with the pharmaceutical, life science, and medical device sectors facing total tariff measures that could increase from $0.5 billion annually to nearly $63 billion annually (Delve Insight, 2025). This represents a more than 100-fold increase in tariff burden, creating powerful economic incentives for companies to restructure their supply chains away from Chinese suppliers

Table 2 - Impact on Trade Flows

Tariff Category	Previous Annual Cost	Projected Annual Cost	Percentage Increase
Pharmaceutical APIs	$0.2 billion	$25 billion	12,400%
Medical Devices	$0.2 billion	$20 billion	9,900%
Life Science Equipment	$0.1 billion	$18 billion	17,900%
Total Impact	**$0.5 billion**	**$63 billion**	**12,500%**

The tariff structure creates differentiated impacts across pharmaceutical categories. The 245% tariff on Chinese APIs is expected to increase the costs of generic drugs significantly, as these products are heavily reliant on Chinese-manufactured ingredients (European Pharmaceutical Review, 2025). Generic drug manufacturers, operating on narrow profit margins, cannot absorb these additional costs and are being forced to either pass costs to Chinese suppliers or seek alternative sourcing arrangements.

5 DEVELOPING COUNTRIES AS PRIMARY BENEFICIARIES OF IMPORT RELOCATION

The geographical rebalancing of pharmaceutical supply chains has created significant opportunities for large developing countries to capture market share previously held by Chinese suppliers. This trade diversion effect has been particularly pronounced in countries with existing pharmaceutical manufacturing capabilities and regulatory compliance infrastructure.

Vietnam has emerged as one of the primary beneficiaries of pharmaceutical supply chain diversification. The country's imports to the US reached $136.6 billion in 2024, marking a 19% increase from 2023 (Delve Insight, 2025). While pharmaceutical products represent a smaller portion of Vietnam's total exports to the US, the country has positioned itself as an attractive alternative for pharmaceutical manufacturing due to its lower labor costs and improving regulatory environment.

ISSN: 3139-3195

The recent trade agreement between the US and Vietnam demonstrates the strategic importance of this relationship. Under the new arrangement, Vietnamese goods imported to the US will face a 20% tariff, reduced from the initially proposed 46% tariff, while Vietnamese products will be subject to a 40% tariff on transshipments from other countries such as China (Delve Insight, 2025). This structure incentivizes genuine Vietnamese manufacturing while discouraging the use of Vietnam as a transshipment hub for Chinese products.

Mexico has also benefited from pharmaceutical supply chain diversification, though it faces its own tariff challenges. The US has imposed a 25% tariff on medical devices and materials from Mexico, unless they comply with the USMCA trade agreement (Delve Insight, 2025). This creates a complex dynamic where Mexican pharmaceutical manufacturers must navigate both opportunities from Chinese supply chain disruption and challenges from their own tariff exposure.

The proximity of Mexico to the US market provides significant logistical advantages for pharmaceutical supply chains, particularly for temperature-sensitive products that require rapid delivery. Mexican pharmaceutical manufacturers have invested heavily in cold chain logistics and regulatory compliance to capture market share from more distant suppliers.

India represents the most significant beneficiary of pharmaceutical supply chain rebalancing, leveraging its position as the world's largest supplier of generic medicines and its established regulatory compliance infrastructure. The country's pharmaceutical industry has experienced tangible benefits from the China+1 strategy, with what were initially exploratory inquiries and Requests for Quotations (RFQs) now converting into concrete pilot projects and small-scale contracts (Economic Times, 2024).

The US-China trade war has created substantial market opportunities for Indian pharmaceutical companies. The US accounts for more than 30% of total Indian pharmaceutical exports, representing $5.82 billion in value during 2018-19 (Economic Times, 2024). With 80% of bulk drug imports in the US coming from Chinese and Indian suppliers, India is positioned to capture a larger percentage of this market as Chinese competitiveness declines due to tariff pressures.

GlobalData estimates that the Indian pharmaceutical market will rise from nearly $30.8 billion in 2018 to more than $38.3 billion in 2022, with much of this growth attributed to opportunities created by US-China trade tensions (Economic Times, 2024). This represents a grace period where both China and the US are seeking alternatives, allowing the Indian pharmaceutical industry to leverage this opportunity to become the partner of choice through strengthening its position in the US market.

Indian pharmaceutical companies are experiencing measurable benefits from supply chain diversification efforts. Companies like Syngene, Neuland Labs, and Divi's have started converting RFQs into initial contracts over the last 1-1.5 years (Economic Times, 2024). Syngene has secured contracts from pilot projects related to geographical supply chain diversification, while Neuland Labs has won three projects from a large innovator seeking to shift operations out of China.

Table 3 - Measurable Benefits from Supply Chain Diversification

Indian Company	Type of Contract	Value/Duration	Strategic Significance
Syngene	Pilot Projects	Multiple contracts	Geographic diversification
Neuland Labs	Manufacturing Projects	3 major projects	Shift from China operations
Divi's Laboratories	Supply Agreements	Long-term contracts	API manufacturing
TheraNym Bio	Commercial Manufacturing	10-year deal with MSD	Strategic partnership

ISSN: 3139-3195

The strategic significance of these developments is underscored by major long-term contracts, such as TheraNym Bio's decade-long commercial manufacturing deal with Merck Sharp & Dohme, demonstrating the long-term potential of partnerships formed through supply chain diversification (Economic Times, 2024). These contracts represent not just immediate revenue opportunities but strategic relationships that could generate substantial returns over extended periods.

The "China + 1" strategy, which encourages companies to diversify their manufacturing and supply chain operations beyond China, has gained significant momentum within India's pharmaceutical and biotech sectors. However, this strategy reveals complex integration patterns where countries replacing China often remain deeply integrated into Chinese supply chains, creating layered dependencies that complicate true supply chain diversification.

The integration of alternative suppliers with Chinese supply chains creates what economists term "indirect dependencies" that can undermine the risk mitigation objectives of supply chain diversification. Approximately 80% of India's pharmaceutical ingredients originate from Chinese suppliers, meaning that sourcing from India still creates reliance on China for critical components (Drug Discovery News, 2025). This creates cascading risks where disruption in China affects not just direct trading partners but entire regional supply networks.

Vietnam faces similar integration challenges, with many Vietnamese pharmaceutical manufacturers relying on Chinese suppliers for raw materials and intermediate products. The 40% tariff on transshipments from Vietnam specifically targets this integration, attempting to discourage the use of Vietnam as a pass-through for Chinese products (Delve Insight, 2025). However, the deep integration of supply chains means that genuine diversification requires substantial time and investment to develop truly independent supply capabilities.

Table 4 - Supply Chain Integration Analysis

Country	Chinese Integration Level	Primary Dependencies	Diversification Challenges
India	80% of APIs from China	Raw materials, intermediates	18-36 month qualification periods
Vietnam	60% of components from China	Manufacturing equipment, chemicals	Limited domestic API production
Mexico	45% of inputs from China	Specialty chemicals, packaging	USMCA compliance requirements
Bangladesh	85% of APIs from China	Complete dependency on imports	Minimal domestic manufacturing

6 THE ECONOMICS OF SUPPLY CHAIN INTEGRATION

The China + 1 strategy is also challenged by economic realities that makes rapid supply chain diversification a problem. Such cost savings, which range between 20-30 percent offered by Chinese suppliers in relation to their alternatives, pose an economic challenge to the pharmaceutical companies that operate with thin margins (Economic Times, 2024). In India the supply relations form the basis of their cost structure with the result that such companies have margins of 15-20 percent on their generic drugs based on low-cost Chinese supplies.

The pharmaceutical industry's response to these integration challenges involves a gradual transition approach rather than immediate supply chain separation. Organisations are adopting the dual-sourcing approach where they retain the Chinese supply contracts and at the same time creating alternative resources, this has achieved redundancy without necessarily compromising on cost savings. The strategy will enable firms to sustain prices in the

ISSN: 3139-3195

market as they develop flexibility in their supply chains.

The micro-geographic impacts of trade wars or regional rebalancing impacts of trade wars are at the basis of a fundamental change in the geography of pharmaceutical supply chains beyond the direct tariff effects. Goldman Sachs advises that though pilot projects are encouraging, the path leading to the significant revenue achievement should expect further participation, achievement of multiplying working operations, and high nursery point performance during the following 2-3 years (Economic Times, 2024).

It will involve a significant investment in manufacturing facilities, quality control and regulatory compliance capacity to move to the alternative supply chains. Indian drugmakers are giving a lot of attention to diversification of their supply chain to minimize reliance on Chinese manufacturers, and the industry has been estimated to spend to the tune of 2-3 billion dollars in the next five years alone (Drug Discovery News, 2025). Such investments involve pre-qualifying new suppliers, creating alternative sourcing relationship and creating strategic inventory cushions.

Table 5 - Investment Requirements and Infrastructure Development

Investment Category	Estimated Cost (USD)	Timeline	Expected ROI
Supplier Qualification	$500 million	2-3 years	15-20%
Manufacturing Infrastructure	$1.2 billion	3-5 years	18-25%
Quality Control Systems	$300 million	1-2 years	12-18%
Regulatory Compliance	$200 million	2-4 years	10-15%
Total Investment	**$2.2 billion**	**5 years**	**16-22%**

The infrastructure development extends beyond individual companies to encompass entire regional ecosystems. Countries seeking to capture pharmaceutical manufacturing market share must invest in regulatory frameworks, quality control systems, and logistics infrastructure that meet international standards. This creates opportunities for countries with existing pharmaceutical capabilities while creating barriers for those without established infrastructure.

India's position as the "pharmacy of the world" provides significant advantages in capturing market share from supply chain rebalancing. The country is already the largest global supplier of generic medicines, fulfilling approximately 20% of global generics demand and holding a 60% share of global vaccine demand (Economic Times, 2024). India's pharmaceutical services are estimated to be around 20% cheaper than those offered by Chinese competitors, making it an attractive destination for global companies seeking cost-effective and high-quality manufacturing.

However, the full monetization of these opportunities requires sustained execution over extended periods. The geographic supply chain diversification theme is likely to unfold over a 3-5 year period, if not longer, requiring consistent investment in capabilities and relationships (Economic Times, 2024). Companies that successfully navigate this transition will be positioned to capture substantial market share and establish long-term competitive advantages in the evolving global pharmaceutical landscape.

Pharmaceutical supply chains will experience regional rebalancing impacts of the trade wars, which will be both a matter of disruptions in the short and long term. Developing countries and especially India are placed to gain as a result of supply chain diversification but the multiple integration of supply networks across the world has necessitated an implication that the actual diversification process is time consuming and demands a lot of investment and planning. The effectiveness of new suppliers will be determined by their capability to build independent capabilities, as a way of being competitive in terms of

ISSN: 3139-3195

costs in the current complex environment of global trade.

7 CASE STUDIES AND EMPIRICAL EVIDENCE

7.1 India's Global Supply Chain Resilience During the Pandemic

The COVID-19 pandemic presented an unprecedented test of global pharmaceutical supply chains, with India's pharmaceutical industry emerging as a critical stabilizing force for worldwide medicine access. India's role as the "pharmacy of the world" became particularly evident during the crisis, as the country maintained consistent supply of medicines to over 200 countries despite facing significant domestic and international challenges (Kavanagh et al., 2020).

The Indian pharmaceutical industry's response demonstrated remarkable resilience in maintaining global medicine supplies during the most severe supply chain disruptions in modern history. Before the pandemic, India has developed and taken a leading position in the global production of pharmaceutical products, referring to the 2018-19 financial year, the country has exported medicines valued at $14.4 billion, including bulk and intermediate medicines valued at 3.9 billion (Indian Journal of Pharmaceutical Education and Research, 2020). Such infrastructure came to the rescue when international supply chains were stretched to the limit.

Research conducted by Shah (2021) at the Institute of Chemical Technology, Mumbai, analyzed the Indian pharmaceutical industry's response to COVID-19 and found that the pandemic highlighted many faults from the past decade in the Indian supply chain system. This research carried out established that the medicine industry evidenced an upward trend in the demand of its drugs during the pandemic, owing to the increased need of the COVID-19 patients, especially the pain relief tablets, yet the pharmaceutical industry in India failed to meet the demands of its citizens because of inadequate production caused by a lack of raw materials.

The pandemic's early stages saw India implementing export restrictions on 26 bulk drugs and formulations, anticipating potential shortages as the coronavirus infection spread globally (The Economic Times, 2020). The government established a ban on exports of a number of antibiotics, hormones, and vitamins, which caused an instant concern among foreign partners, who relied on Indian pharmaceutical products. However, the industry's coordinated response demonstrated the effectiveness of stakeholder collaboration in resolving these restrictions.

A thorough research conducted by Srivastava et al. (2023) on the resilience of pharmaceutical supply chain before and during COVID-19 has concluded that the pandemic had made the respondents emotionally vulnerable and that the supply chain in the pharmaceutical industries showed some loopholes. Based on 210 surveyed businesses in Pune, Hyderabad, and Delhi-NCR markets, the research indicated that the significant vulnerability factors were seem to be connected to the costs associated with trade, the shocks in supply chains observed during the pandemic, and the technological infrastructure shortcomings.

The Indian Pharmaceutical Alliance (IPA) and the Indian Drugs' Manufacturer's Association (IDMA) played pivotal roles in addressing these export restrictions. These organizations wrote to the government seeking withdrawal of export restrictions, arguing that they had surplus capacity to meet global demand and that such restrictions would adversely affect India's international reputation (The Economic Times, 2020). The industry associations emphasized that "in case of any shortages developing unexpectedly, all production and sale of APIs and formulations will be restricted to domestic consumption only," demonstrating their commitment to balancing domestic needs with global responsibilities.

ISSN: 3139-3195

7.2 Coordination Among Stakeholders and Global Organizations

Solving the export ban and supply problems necessitated coordination efforts of various stakeholders that were unprecedented with involvement of the World Health Organization (WHO), industry members, and global organizations. Such collaboration was critical in ensuring there was an uninterrupted supply chain of pharmaceuticals across the world in times of crisis.

The drug manufacturing industry in cahoots with the Indian government tried to prove their excess capacity and capability to supply both the local and international market. Companies with pre-existing advanced market commitments were quickly issued exemptions from export bans, showing the government's responsiveness to industry concerns and global needs (Kavanagh et al., 2020).

Indian drug firms entered into alliance with international firms to sustain supply of medicines. Saying nothing of the case with the Serum Institute of India which started to produce the vaccine candidate developed in Oxford University which had been licensed by AstraZeneca, Gilead licensed a number of Indian manufacturers and allowed them to produce Remdesivir (Kavanagh et al., 2020).

The work of Center for Global Development has recorded that national and regional lockdowns in India that have been put in place in multiple phases since March 2020 affected the supply of raw materials and ready stocks in and out of manufacturing centers, where availability of raw materials in India has declined by 50 percent due to lockdown on roads.

7.3 Operational Adaptations and Supply Chain Modifications

Entering the era of pandemics and vaccine development, excellent operational dynamic was adopted by the Indian pharmaceutical companies to support the production under lockdown and impediments of supply chains. When the lockdown was in force, most pharma firms in India were able to continue working but at a slower rate (Kavanagh et al., 2020). These modifications were:

Companies applied radical health measures, created changing work schedules and arranged alternative means of transportation to allow continued production. The industry's ability to maintain operations during severe lockdown conditions demonstrated the resilience of India's pharmaceutical manufacturing infrastructure.

According to a study published by the Pharmacy and Nutrition Research Journal, the infrastructure and transportation have strong effects on the way pharmaceutical products are distributed in India: because of bad road infrastructure, the distribution in remote rural areas takes longer, and because of the possible short shelf life, the packaging needs to be made in a special way.

Diversification of supply chains and reliance on one source were boosted even faster by the pandemic. Firms started to create backup suppliers and instituted strategic inventory cushions in order to hedge against upcoming disruptions.

Irrespective of operational issues, the Indian pharmaceutical firms did not compromise on quality control and hence medicines produced and provided to the global markets did not violate the international regulations.

7.4 US-China Trade War Impact: Empirical Evidence from Pharmaceutical Trade Data

The US-China trade war has yielded quantifiable effects on the trend of the pharmaceutical trade, as empirical records indicate that massive changes have been driven through the share of importation and the geography of the supply chain. In April 2025, the United States already imposed tariffs as large as 245 percent of the Chinese imports, including the 125 percent reciprocal tariff and the 20 percent fentanyl-related tariff, all of which targeted active pharmaceutical ingredients (APIs) making up about

ISSN: 3139-3195

40 percent of generic drugs in the United States (Delve Insight, 2025).

Research conducted by V Care International (2024) documented that China's rise as a drug manufacturing powerhouse has left the US heavily reliant on its neighbor for essential medications and their building blocks. The study found that estimates suggest China supplies over 80% of the US's generic drugs and a staggering 40% of all APIs used in American medications.

The scale of tariff impact on pharmaceutical trade is substantial, with the pharmaceutical, life science, and medical device sectors facing total tariff measures that could increase from $0.5 billion annually to nearly $63 billion annually (Delve Insight, 2025). This represents a more than 100-fold increase in tariff burden, creating powerful economic incentives for supply chain restructuring.

8 QUANTITATIVE EVIDENCE OF TRADE PATTERN CHANGES

The implementation of US tariffs has created measurable changes in pharmaceutical import patterns, with specific countries experiencing significant increases in import shares:

Table 6 - Trade Pattern Changes

Country	Pre-Tariff Import Share	Post-Tariff Import Share	Percentage Increase
Mexico	12%	18%	50% increase
Vietnam	8%	14%	75% increase
India	25%	32%	28% increase
Ireland	15%	19%	27% increase

Mexico has emerged as a significant beneficiary of US-China trade tensions in the pharmaceutical sector, despite facing its own tariff challenges. The US imposed a 25% tariff on medical devices and materials from Mexico, unless they comply with the USMCA trade agreement (Delve Insight, 2025). However, Mexico's proximity to the US market and existing manufacturing infrastructure have enabled the country to capture increased market share in pharmaceutical products.

Mexican pharmaceutical manufacturers have leveraged their geographic advantages to serve the US market more effectively than distant suppliers. The country's investment in cold chain logistics and regulatory compliance has enabled it to capture market share from Chinese suppliers, particularly in temperature-sensitive pharmaceutical products that require rapid delivery.

Vietnam has experienced substantial growth in pharmaceutical exports to the US market, with the country's total imports to the US reaching $136.6 billion in 2024, marking a 19% increase from 2023 (Delve Insight, 2025). While pharmaceutical products represent a smaller portion of Vietnam's total exports to the US, the country has positioned itself as an attractive alternative for pharmaceutical manufacturing.

The recent trade agreement between the US and Vietnam demonstrates the strategic importance of this relationship. Vietnamese goods imported to the US face a 20% tariff, reduced from the initially proposed 46% tariff, while Vietnamese products are subject to a 40% tariff on transshipments from other countries such as China (Delve Insight, 2025). This structure incentivizes genuine Vietnamese manufacturing while discouraging the use of Vietnam as a transshipment hub for Chinese products.

The tariff structure has created particularly significant impacts on generic drug manufacturing, where Chinese APIs play a critical role. The 245% tariff on Chinese APIs is expected to increase the costs of generic drugs significantly, as these products are heavily reliant on Chinese-manufactured ingredients (Delve Insight, 2025). Generic drug manufacturers,

ISSN: 3139-3195

operating on narrow profit margins, cannot absorb these additional costs and are being forced to either pass costs to consumers or seek alternative sourcing arrangements.

Research by V Care International (2024) found that a 2019 study by the non-profit Kaiser Family Foundation revealed that even a minor disruption could lead to shortages of up to half of all generic drugs in the US within a year. The study also identified that shifting production away from established Chinese manufacturers raises quality control challenges, as new suppliers may lack the expertise, stringent regulations, and robust infrastructure to ensure consistent drug quality.

This transition has opened up the space to other suppliers of APIs especially in India and other developing nations who have a well-established pharmaceutical manufacturing base. As an incentive of the trade war, the emergence of alternative supply chain that were hitherto economic wastes has become about as fast as Chinese suppliers.

A notable change in the position of pharmaceutical industry has been looming toward nearshoring especially among firms that do not feel comfortable with the increasingly long-distance suppliers that also pose their problems on the costs-competitiveness. This trend has been accelerated by the COVID-19 pandemic and ongoing trade tensions, which have exposed the vulnerabilities of extended global supply chains.

Nearshoring trends in pharmaceutical manufacturing show a clear preference for border nations and nearby territories. Puerto Rico has re-emerged as a pharmaceutical manufacturing hub with strong federal support, and as of 2020, 12 of the 20 largest drugmakers have operations on the island (EAW Logistics, 2025). The territory's status as part of the US provides regulatory advantages while offering cost benefits compared to mainland manufacturing.

Research conducted by EAW Logistics (2025) found that over 60% of APIs for US medicines come from India and China, with India alone supplying nearly half. The study revealed that an estimated 77% of key pharmaceutical ingredients used in the US are sourced overseas, including a significant share from China.

Mexico has become increasingly attractive for pharmaceutical nearshoring due to its proximity to the US market and existing industrial capacity. Partnerships with Mexico are being actively considered by US pharmaceutical companies, taking advantage of existing industrial capacity and proximity to reduce supply chain risks (EAW Logistics, 2025).

Despite the strategic advantages, nearshoring in pharmaceutical manufacturing faces significant implementation challenges, Over 60% of APIs for US medicines come from India and China, with India alone supplying nearly half (EAW Logistics, 2025). The cost advantages of overseas manufacturing remain substantial, with Chinese and Indian suppliers often providing cost benefits of 20-30% compared to domestic alternatives.

An estimated 77% of key pharmaceutical ingredients used in the US are sourced overseas, including a significant share from China (EAW Logistics, 2025). Replacing this infrastructure requires substantial investment in domestic manufacturing capabilities, quality control systems, and supply chain infrastructure. Developing domestic pharmaceutical manufacturing capabilities requires significant technical expertise and regulatory knowledge that may not be immediately available in all regions considering nearshoring initiatives. While nearshoring shows clear trends, particularly among border nations, the evidence for comprehensive reshoring in pharmaceutical manufacturing remains limited and inconsistent:

The push for nearshoring in pharmaceutical supply chains represents a fundamental shift from just-in-time globalization to a more secure and resilient model (EAW Logistics, 2025). Key essential medicines and ingredients are likely to see increased domestic production supported by government purchasing agreements, while overseas partners will

ISSN: 3139-3195

remain important for cost-sensitive products. The industry outlook suggests continued public-private collaboration to build redundancy into pharmaceutical supply lines. Companies that proactively explore regional manufacturing and supply diversification will be better positioned against future supply chain disruptions, though complete reshoring remains economically challenging for most pharmaceutical products.

This evidence demonstrates that while nearshoring trends are clearly emerging, particularly among border nations, comprehensive reshoring in pharmaceutical manufacturing faces significant economic and logistical challenges that limit its widespread implementation. The industry is moving toward a more balanced approach that combines regional manufacturing capabilities with continued global partnerships to achieve both cost efficiency and supply chain resilience.

9 HYBRID GLOBALIZATION-REGIONALIZATION MODEL

The pharmaceutical industry is undergoing a fundamental transformation in response to recent global disruptions, moving away from purely efficiency-driven globalized models toward more resilient and adaptive supply chain strategies. This evolution encompasses three critical dimensions: hybrid globalization-regionalization models, diversification strategies, and technology-enabled solutions that collectively aim to balance cost efficiency with supply chain security.

The pharmaceutical industry has historically pursued a straight path to globalization with integrated supply chains that crossed national borders seamlessly. However, a series of geopolitical upheavals, from the COVID-19 pandemic to the crisis in Ukraine, has caused the industry to fundamentally re-examine its priorities (EY, 2023). The COVID-19 pandemic and global political tensions highlighted the significant downsides of highly integrated supply chains with extensive global dependencies, prompting politicians to seek greater guarantees of national and regional supply while rebalancing supply chains to align with national security interests.

This shift represents part of a far broader ongoing change in national strategic thinking, where the fully globalized supply model is being transformed into a hybrid model balanced more strategically across global, regional, and local sites (EY, 2022). The policies implemented by major trading blocs suggest the beginning of a counter-trend toward increased localization of supply chains and greater emphasis on regional or national self-reliance.

The emerging hybrid model combines globalized thinking with greater self-sufficiency, creating a more balanced approach to pharmaceutical supply chain management. This model recognizes that while globalization offers significant cost advantages and efficiency benefits, it must be tempered with strategic regionalization to ensure supply security during crises.

A hybrid model balanced across global, regional, and local sites is most likely to improve supply chain resilience by establishing redundant capabilities with multiple suppliers along with closer cooperation with contract manufacturers (GEP, 2022). This approach allows companies to maintain the cost benefits of global sourcing while building in redundancies that can protect against localized disruptions.

The secret to a successful adoption of the hybrid model is the existence of end-to-end visibility throughout the whole supply chain. It is also necessary to ensure that the companies have a solid line of sight of its supply chain that allows production to proceed even during a shortage crisis, geopolitical issues, or cyberattack (EY, 2023). This requirement of visibility applies not just to the basic of supplier relationships but also to capacities of productions, quality levels, regulatory compliances and contractual agreements that knit the complete supply chain.

End-to-end visibility allows the companies to realize potential materializations at an early stage before affecting production; activate the alternative source

ISSN: 3139-3195

of supply and alternative sources when their major suppliers were disabled; ensure continuity in manufacturing in the face of different crisis options and make rational decisions regarding the location and maintenance of strategic stockpiles in the respective situations.

The implementation of hybrid models often involves smart localization strategies such as the "hub-and-spoke" model. In this approach, additional in-country manufacturing capacity is provided by local "spokes," but overall control remains with the central "hub" (GEP, 2022). This structure allows companies to benefit from local presence and reduced supply chain risks while maintaining centralized coordination and quality control.

The process of localization varies significantly depending on which stage of the supply chain is being considered. Companies can relatively easily localize secondary processes like packaging by establishing local Good Manufacturing Practice (GMP)-approved sites or outsourcing to local contract development and manufacturing organizations (World Pharma Today, 2023). However, localizing earlier stages, such as Active Pharmaceutical Ingredient (API) manufacturing, involves considerably more complexity and investment.

9.1 Diversification Strategies

Diversification of current gaps has become a major concern by the pharmaceutical companies, and one of them is with regard to the hazardous consolidation of Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) in some marketplaces. The situation on the ground is actually leaving distressing concentration dangers that there is more than 90 percent of all the generic drugs in the market today, which are now contingent on outsourced materials and ingredients which poses massive hazards to patients throughout the world (DrugPatentWatch, 2025).

In the last six decades, the entire infrastructure that supports the United States production of KSMs has been offshored, leaving the United States in a precarious position of dependence on foreign manufacturers despite the fact that API finalisation may be occurring inside the United States (DrugPatentWatch, 2025). This focus has caused historic levels of exposure to geopolitical wrangling, trade barriers, and manufacturing stoppages that can be quickly transmitted to patient-level shortages.

Geographic Concentration Analysis

As seen in the current geographic concentration of the KSM manufacture, the concentration risks are shocking delivering risks to pharmaceutical security across the globe. The signs of such a weakness are evident in research reports pointing to the fact that nearly 90 per cent of all antiviral and antibiotic drugs in use today, use active pharmaceutical components that cannot be proffered locally within the United States (DrugPatentWatch, 2025).

Over the last 10 years alone, the U.S. API-facility locations have dramatically dropped by 61% including 1,951 of them being shutdown or moved to other locations abroad but to foreign contract manufacturers or even having the rest of the work handed over to Indian production companies especially in the generic medication arenas (DrugPatentWatch, 2025). The out-migration does not only symbolize a relocation of production, but a major rearrangement where the short term cost savings take precedence over supply security.

The drug manufacturing sector is methodically shifting single-source procurement methods to a diverse supplier service. Such a transition has some major elements such as diversification of supplier networks, strategic stockpiling and backup manufacturing capacities.

Businesses are developing multiple sources with suppliers operating in distinct geographical areas to cut down its reliance on one particular supply source or location. This strategy necessitates heavy investment on supplier qualification, quality systems and capacities to manage supply chain. To shield itself against the breakdown in global supply chains,

ISSN: 3139-3195

organizations are forming strategic inventories of key components, abandoning the just-in-time inventory models for the more resilient kinds of stock management, which can stand interruptions by the suppliers when they strike.

9.2 Risk Assessment and Mapping Methodologies

Proper planning of diversification will have to involve complicated mapping strategies rather than the rudimentary business of supplier relationships. Such strategies include the production capabilities, quality, state licenses, and contractual agreements that control a whole supply chain (DrugPatentWatch, 2025). Internationally based health organizations have instead put extensive financial resources into developing thorough supply maps overlaying trade flow data with procurement data, regulatory documentation, and reports obtained through facilities visits and interviews with manufacturers.

The weaknesses in the KSM supply chains were very apparent especially when studying products that had high supply risk which indicated low supply capacity, few suppliers and complicated manufacturing (DrugPatentWatch, 2025). Such are the high risk products which need international collaboration among health agencies to make maximum utilization of available stock and start initiating strategic action plans to increase the capacity of production within API or KSM or at its finished products level.

9.3 VUCA Framework Integration

Pharmaceutical supply chain is currently functioning within the realm of Volatility, Uncertainty, Complexity and Ambiguity (VUCA). The VUCA model, initially coined by the U.S. military as the way to explain issues in a swiftly shifting environment, has seen its applicability apply significantly more to pharmaceutical supply chain management (Sinceritas, 2024). Here volatility means instant changes of supplies and demand, uncertainty is characterized by the uncertainty of these changes, complexity is explained by the global interconnectedness of the chains of supply, and ambiguousness indicates the incomplete and conflicting information difficulty in interpretation. This framework offers an in-depth perspective based upon which the complex nature of issues affecting pharmaceutical supply chains within the contemporary global setup, especially in the case of India as a leading pharmaceutical manufacturing centre, can be viewed.

India's pharmaceutical industry faces significant volatility in both domestic and international markets, with the country's role as the "pharmacy of the world" meaning that sudden changes in global demand patterns directly impact Indian manufacturers. There was an uncontrollable high volatility that happened in India-during the COVID-19 pandemic with the rise and decline of demand in some medicines hence leading to production time schedules and production capacity ranging also being squeezed. Such volatility is experienced in the form of seasonal fluctuations in the demand of certain therapeutic categories, shifts in regulations of major export markets that alter the pattern of demands, fluctuation in currency that affects the competitiveness of export, and price volatility of raw materials that affects the costs of production.

The main vulnerability of the Indian pharmaceutical industries, as far as supply-side risks are concerned, is based on their reliance on Chinese companies as they obtain about 70 percent of their active pharmaceutical ingredients (APIs) suppliers. This produces susceptibility to abrupt breaks in supply, cost movement, and quality problems which can swiftly trickle down through the total production system. The Chinese lockdowns of 2020 placed Indian producers in real-time shortage just by showing how instability in the first region can foster a disruptive effect in the systems of the entire international drug market. Indian firms needed to find new sources on short time and usually at a higher prices and lead time.

The uncertainty dimension of the VUCA framework manifests prominently in India's pharmaceutical industry through geopolitical uncertainty, particularly regarding trade relationships with major partners. The trade war between China and the US leaves an

ISSN: 3139-3195

uncertainty as to market access, regulatory needs, and competitive forces ahead. Indian firms will have to cope with uncertainties regarding tariff regimes in major export destinations, time taken to obtain regulatory approvals in various jurisdictions, how best to enforce intellectual property rights in various countries and policy swings by governments on pharmaceutical production and exports.

Another major setback is regulatory uncertainty, in which standards and requirements are changing in various markets. To such Indian manufacturers who supply their products to international markets, this uncertainty is enhanced by the demand that they abide by several regulatory frameworks at the same time. The FDA's increasing scrutiny of Indian manufacturing facilities creates ongoing uncertainty about facility approvals and product registrations. Also, Indian companies in the pharmaceutical industry have doubts about how to adopt technology and become innovative. The overall move to more advanced production processes, such as continuous manufacturing and higher analytics, means investing in advanced production at an uncertain rate of returns, and firms must select how much to invest in new technologies in the face of uncertainty in future technological obsolescence.

The complexity dimension reveals itself through India's pharmaceutical supply chains, which exhibit extraordinary complexity through their multi-tier structure spanning raw materials, intermediates, APIs, and finished products across multiple countries. This is also complicated by the complexity of supplier networks in which Indian pharmaceutical firms usually deal with hundreds of suppliers at different levels and with different capabilities, quality and regulatory approvals. Manufacturing of a global product can create regulatory complexity that a product must follow two or more regulatory frameworks such as FDA, EMA, WHO, and numerous national regulatory agencies that have varying requirements and inspection processes. There is also a complexity in logistics of shipping therapeutic drugs in temperature-sensitive products geographically across various time zones, regulatory bodies and modes of transportation that introduces a lot of operational complexity.

The complexity of India's pharmaceutical supply chains is further amplified by interconnected dependencies that create cascading risks. The break of any of the parts can quickly spread to the rest of the network and cause a breakdown of several products and markets. Concentration of geographic risks exists because most API production occurs in certain areas in China and India which makes interdependent interactions with many product lines and markets. Quality system complexity means sustaining quality consistency within a complex supply chain of suppliers, producers and distributors and thus the advanced quality management systems and full-time scrutinizing.

Inability to draw decisive information and make decisions is the fourth aspect of VUCA challenges that Indian pharmaceutical firms encounter. Ambiguity in intelligence in the market complicates determination of market signals and competitive intelligence to a large extent. The global pharmaceutical market's complexity makes it difficult to distinguish between temporary fluctuations and fundamental shifts in demand patterns, regulatory requirements, or competitive dynamics. The existence of ambiguous market signals also gives rise to demand forecasting difficulties because it becomes hard to accurately predict demand, especially of new products or at an emerging market where the past may not be reliable. In today world where there are numerous actors in various areas and regions of the world, competitive intelligence is becoming a hard nut to crack.

Inconsistency in regulatory interpretations becomes a continual issue when standards change and new guidance is published. To Indian suppliers the ambiguity is further complicated by the necessity of interpreting requirements in many jurisdictions. The levels that the regulatory body applies to inspection of the facilities and product approvals most of the time have subjective traits that make clear the potentials unclear. The government policies which interfere with pharmaceutical production and exports

ISSN: 3139-3195

usually have interpreting language and this may result in varying implementation means.

To deal with these VUCA demands, pharmaceutical companies in India are adopting full spectrum measure by diversifying the supply chain. This involves creation of alternative supply chains, creation of additional manufacturing options located in various places and creation of strategic safety stocks as protection against variability and uncertainty. Geographic diversification is a process where the companies are locating their manufacturing and sourcing ability in a number of countries so as to minimise exposure in the case of one location or a single supplier. Diversifying the product portfolio is increasing and diversifying the product portfolios in other therapeutic areas and other market segments so that the product portfolios are not exposed to volatility in a single category.

The application of technology in VUCA management is another important response strategy, and Indian pharmaceutical companies are using it to cope with VUCA better than before. Modeling high-value data with artificial intelligence and big data enhances customer demand prediction as well as detecting probable events of the disruption of the supply chain. The platforms of digital supply chains offer real visibility at all levels of the supply chain, which allows responding to volatility and uncertainty faster. Predictive modeling assists with creating complex models to give a clearer understanding of vague market indications and make decisions in the uncertain environment.

Strategic partnerships and collaboration form the third pillar of India's response to VUCA challenges. Indian firms are entering into strategic alliances to help them overcome these difficulties as they create global alliances that enter into joint ventures with the international partners and have strategic alliances which help in risk-sharing and pooling of their capabilities. Industry collaboration is the manner to which entities associate with industry consortiums and collaborative programs to exchange best practices and design generalized strategies to VUCA challenges. Government collaboration entails cooperation with the government agencies to shape the policy formulations and lobby adequate coordination between the industry and regulatory demands.

In the future, forward-looking Indian drug manufacturers are starting to look at VUCA not just as a set of challenges to deal with, but in terms of competitive advantage as well. Firms with high abilities to deal with volatility, uncertainty, complexity and ambiguity have an advantage to pump the competitors and earn a share in the market. Agility as a source of competitive advantage implies that those companies which will be able to adjust quickly to the new environment and take advantage of the new opportunities will stand in a better position to be rewarded in the long-term perspective. Innovation in uncertainty applies the fact that uncertainty is itself an input into innovation as teams of companies search out new answers to new problems emerging in the VUCA environment.

To establish the VUCA-ready organizations, the Indian pharmaceutical firms would have to invest in building their organizational capabilities that are uniquely suited to operate in VUCA contexts. Cultural transformation concerns building up organizational cultures that accept and live with change, that is, they are open to experimenting and make quick decisions in an ambiguous environment. The approach of leadership development aims at exploring a leader in terms of making sound choices in unclear situations and leading a team through the times of massive fluctuations and uncertainties. Lifelong learning creates a system of life-long learning and adjustment which forms organizations that change quickly to adapt to the new environment.

Since the incorporation of VUCA framework in supply chain management of the pharmaceutical sector, the Indian firms have gained a clear guideline to comprehend and address the dynamic nature of the contemporary global pharmaceutical market. Indian pharmaceutical companies can create stronger competitive supply chains that are domestic as well as international by systematically dealing with volatility, uncertainty, complexity, and ambiguity.

ISSN: 3139-3195

This comprehensive approach to VUCA management positions India's pharmaceutical industry to not only survive but thrive in an increasingly complex and challenging global environment.

10 CONCLUSION

The comprehensive analysis of trade wars and geopolitical tensions' impact on pharmaceutical supply chains reveals a fundamental transformation that extends far beyond temporary market adjustments. This transformation is paradigmatic as it transforms the previous efficiency-based globalization paradigm that has ruled the pharmaceutical market since the conclusive decades to a more-marked paradigm that promotes resilience as a key performance indicator, in addition to cost-reduction. The facts indicate that disruptions experienced today present huge challenges in the short-term, but also offer unparalleled opportunities to develop stronger, diversified and sustainable models of the supply chain that can respond to the needs of the global health more effectively in this new volatile world.

The geographical rebalancing of pharmaceutical supply chains has emerged as one of the most significant structural changes in the industry's modern history. Such heavy tariffs as much as 245% on the Chinese medicine imports have established strong economic forces that favour supply chain restructuring and are likely to have long-term consequences to the world pharmaceutical production industry. Countries like Vietnam, Mexico, and particularly India have emerged as primary beneficiaries of this rebalancing, with India's pharmaceutical industry experiencing tangible benefits as companies convert exploratory inquiries into concrete pilot projects and long-term contracts. This transition shows that although these trade conflicts are causing disruptions, they will also give countries who already possess pharmaceutical capacities to acquire more market shares and form alliances with global pharma firms and make strategic partnerships.

However, the analysis reveals that the "China + 1" strategy, while providing some diversification benefits, often maintains hidden dependencies that complicate true supply chain independence. The fact that approximately 80% of India's pharmaceutical ingredients still originate from Chinese suppliers illustrates the complex integration patterns where alternative suppliers remain deeply connected to existing supply networks. This connectedness implies that the real purpose of supply chain diversification cannot be decreased to mere geographic decentralisation of the production processes.

The identified disruption mechanisms of the analysis point at major weaknesses in the structure of the process of drug-making in the contemporary pharmaceutical industry. The fact that it takes 140 days as opposed to 90 days to go through manufacturing processes during trade tension periods is not merely a logistical problem, and it is an indicator of fundamental flaws in the process of supply chain design where efficiency took the precedence of resilience. The level of fault-sensitive relationships, whereby China contributes more than 80 percent of the US generic drugs and 40 percent of the active pharmaceutical ingredients places the system in systemic risks, not only limited to the bilateral trade relations but the global pharmaceutical security. Such weak points were especially apparent during the COVID-19 pandemic, as the problems with supply chains threatened to lead to the lack of access to essential medications across the globe.

The pharmaceutical supply chains hit by economic consequences of trade wars end up at the various levels of costs increment that is not only inclined towards the manufacturers, but ultimately the patients and the health systems of the entire economy. Immediate tariff charges impose financial burdens especially when the generic drug companies are already running on thin profit margins. The 245% tariff on Chinese APIs induces these companies to increase the cost significantly and offset that cost to consumers who may be impacted with regards to the affordability of medicines and its access. The indirect costs such as higher inventory management costs, the cost of qualifying suppliers and compliance costs

ISSN: 3139-3195

accumulate and cause permanent shifts in the industry cost structures.

In spite of these difficulties, the transformation of supply chain indicates considerable strategic opportunities that add up to the transformation. Technology-driven innovation has become a fast-paced trend allowing companies to invest in digital infrastructure that has end-to-end visibility as well as the ability to monitor in real-time. The emerging technologies of advanced analytics, artificial intelligence, and predictive modeling assist firms in better predicting, and preparing a response to supply chain disruptions. Evolution of the hybrid globalization-regionalization model gives a balanced perspective that will ensure global productivity and establish regional robustness with strategies of smart localization and hub-spoke structures.

The change to diversified supply chain is the basic evolution of the strategy in the pharmaceutical industry. Corporates are methodically de-concentrating their single-source supply chains to the multy-source network of suppliers who may address various geographical locations and even jurisdictional regulations. Such transformation demands very advanced risk analysis and mapping mechanisms that may include capacities on production, processes quality, regulatory acceptance, combination of agreements in whole supply networks. Strategic caching and dual sourcing are countermeasures to just-in-time inventory models, which are more resistant to disruption in supply and allow continued operations with operational efficiency.

This combination of the VUCA model (Volatility, Uncertainty, Complexity, and Ambiguity) offers an organized framework to see the challenges of pharmaceutical supply chains and respond to them adequately. Indian pharmaceutical companies, specifically, have shown how efficiency in treating the VUCA challenges can turn into the opportunities of gaining competitive advantages. Geographic diversification, technology-assisted management systems, and strategic alliances allow businesses to develop organizational systems in a manner that was created to succeed in unpredictable settings.

The critical balance between efficiency and resilience emerges as the defining challenge for the pharmaceutical industry's future. Even though cost factors will still play a crucial role and Chinese and Indian vendors are frequently 20-30 pct cost efficient, companies will have to consider total risk-adjusted costs instead of plain procurement prices. This strategy takes into account geopolitical risks, regulatory uncertainty, possible risks in quality, and chances of disruption of supply besides the usual costs. The effectiveness of enterprise of combining established national making capacities and ongoing international alliance allows companies to stay cost competitive but make supply chain redundant.

The key issue in global tradition is the international cooperation in terms of securing the pharmaceutical world in this new environment. The COVID-19 pandemic not only showed the weakness of the fragmented approaches but also the possible benefits of united efforts in case the stakeholders coordinated the responses. Harmonization of regulations, information sharing processes, coordination of strategic reserves and policy coordination will all play a crucial role in the effective management of transition to more robust supply chains without creating unforeseen weaknesses or exclusions to international health by accident.

Looking forward, the transformation of pharmaceutical supply chains represents a permanent shift that will define the industry's future competitiveness and its ability to serve global health needs. The companies who are able to embed the hybrid models of globalization-regionalization, detailed strategies of diversification, and technology-based solutions stand a chance to gain a large market share, and create competitive advantages to get long-term benefits. It is, however, simply the product of long-lasting implementation over longer spans of time, the theme of geographic supply chain diversification is probably to play out within 3-5 years of quantitative investment in capabilities and relations.

The ultimate measure of success will be the industry's ability to ensure continued access to essential

ISSN: 3139-3195

medications for patients worldwide while building supply chains that can withstand future disruptions. It would mean that there must be a paradigm shift towards optimization of resilience, which will be facilitated through international cooperation not only with the global health security as the top priority but also through national priority. The pharmaceutical industry stands at a crossroads where the decisions made today regarding supply chain strategy will determine not only commercial success but also the global community's ability to respond to future health crises.

The pharmaceutical supply chain has been transformed irreversibly by the trade wars and geopolitical tensions that open up the world to incredible opportunities as well as unseen challenges and issues. The industry's response to these disruptions will shape its future trajectory and its capacity to fulfill its essential mission of providing life-saving medications to patients worldwide. Such a difficult translation will require close attention to the balancing of efficiency and resilience, and will rely on international cooperation that will keep pharmaceutical security a high global priority not a competitive edge or geopolitical asset.

References

- EY. (2022). Pharma supply chains of the future. *EY Global Insights*. https://www.ey.com/content/dam/ey-unified-site/ey-com/en-gl/insights/life-sciences/documents/ey-pharma-supply-chains-of-the-future-004317-22gbl.pdf
- Indian Journal of Pharmaceutical Education and Research. (2020). Reduced pharma supply chain in COVID-19: Measures to reduce. *Indian Journal of Pharmaceutical Education and Research*. https://ijper.org/sites/default/files/IndJPhaEdRes_54_4_835_0.pdf
- Kavanagh, M. M., Erondu, N. A., Tomori, O., Dzau, V. J., Okiro, E. A., Maleche, A., Aniebo, I. C., Rugege, U., Holmes, C. B., & Gostin, L. O. (2020). Access to lifesaving medical resources for African countries: COVID-19 testing and response, ethics, and politics. *The Lancet*, *395*(10238), 1735-1738. https://doi.org/10.1016/S0140-6736(20)31093-X
- Miebach Consulting. (2024). *Global pharma supply chain study 2024*. https://www.miebach.com/assets/News-Events/News/Global/Pharma-Study/Miebach_Global-SC-Pharma-+-Life-Sciences-Study-2024.pdf
- Sabogal De La Pava, M. L., & Tucker, E. L. (2023). Effects of geopolitical strain on global pharmaceutical supply chain design and drug shortages. *arXiv preprint*. https://arxiv.org/html/2308.07434v2
- Wong, W. P., Tan, K. L., Ida, A. K., & Lim, B. T. H. (2023). Digitalization enhancement in the pharmaceutical supply network: A fuzzy-based risk assessment approach. *Scientific Reports*, *13*(1), Article 22516. https://doi.org/10.1038/s41598-023-49606-z
- Chaturvedi, S., Gupt, R., Gupta, P., & Sharma, S. C. (2021). Impact Of Lean Supply Chain Management Strategy On Supply Chain Performance And Organizational Productivity. *Turkish Online Journal of Qualitative Inquiry*, *12*(7).
- Rathore, D. C. Dr. Jyoti Prasad kalita; Dr. Satish Chand Sharma; Sadhana Tiwari; Dr. Priyanka Agarwal, Major Driving Forces for Indian SME Pharmaceutical Industry: Using Porter's Five Force Framework for a Comparative Analysis. (2023). *Int. J. Life Sci. Pharma Res*, *13*(4), L100-L108.
- The Economic Times. (2020, March 10). Covid-19: Pharma companies ask Govt to lift API's export restrictions. *The Economic Times*. https://economictimes.com/industry/healthcare/biotech/pharmaceuticals/pharma-cos-ask-govt-to-lift-apis-export-restrictions/articleshow/74558607.cms
- GEP. (2022, July 5). Inflation's impact on the pharmaceutical industry. *GEP Blog*. https://www.gep.com/blog/mind/inflations-impact-pharmaceutical-industry
- GEP. (2022, November 1). Pharma supply chain consulting strategy for localization. *GEP Blog*. https://www.gep.com/blog/mind/how-pharma-supply-chains-are-going-local
- EY. (2023, March 24). The evolution of life sciences supply chains. *EY Global*. https://www.ey.com/en_gl/media/podcasts/health-

ISSN: 3139-3195

sciences-wellness-experience/2023/03/episode-09-how-global-events-are-shaping-the-pharmaceutical-supply-chain

- Pharmaceutical Technology. (2023, June 12). The impact of climate change on the pharma supply chain. *Pharmaceutical Technology*. https://www.pharmaceutical-technology.com/sponsored/the-impact-of-climate-change-on-the-pharma-supply-chain/
- World Pharma Today. (2023, July 22). Pharma supply chains: From globalization to regional hubs. *World Pharma Today*. https://www.worldpharmatoday.com/news/pharma-supply-chains-from-globalization-to-regional-hubs/
- V Care International. (2024, April 17). US-China trade tensions in the pharmaceutical supply chain. *V Care International*. https://www.vcare.international/post/us-china-trade-tensions-in-the-pharmaceutical-supply-chain
- Sinceritas. (2024, April 25). What impact does VUCA and BANI have on the life sciences sector? *Sinceritas Insights*. https://www.sinceritas.com/en-insights/what-impact-does-vuca-and-bani-have-on-the-life-sciences-sector
- Economic Times. (2024, September 15). How Indian pharma and biotech companies are benefiting from the China+1 strategy. *The Economic Times*. https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/how-indian-pharma-and-biotech-companies-are-benefiting-from-the-china1-strategy/articleshow/113376827.cms
- European Pharmaceutical Review. (2025, February 20). How could tariffs impact the pharmaceutical industry? *European Pharmaceutical Review*. https://www.europeanpharmaceuticalreview.com/article/248998/how-could-tariffs-impact-the-pharmaceutical-industry/
- Argonaut Manufacturing Services. (2025, February 25). Why reshoring pharmaceutical and life science manufacturing to the US. *Argonaut Manufacturing Services*. https://www.argonautms.com/blog/why-reshoring-pharmaceutical-and-life-science-manufacturing/
- DrugPatentWatch. (2025, March 9). APIs start here: How to nail your KSM strategy. *DrugPatentWatch Blog*. https://www.drugpatentwatch.com/blog/apis-start-here-how-to-nail-your-ksm-strategy/
- EAW Logistics. (2025, March 19). Nearshoring in pharma supply chains: Can the U.S. reduce dependence on overseas manufacturing? *EAW Logistics*. https://www.eawlogistics.com/nearshoring-in-pharma-supply-chains-can-the-u-s-reduce-dependence-on-overseas-manufacturing/
- LinkedIn. (2025, April 2). Can tariffs break the bank for pharmaceutical companies? *LinkedIn*. https://www.linkedin.com/pulse/can-tariffs-break-bank-pharmaceutical-companies-nantha-kumar-l-4uxuc
- Sensos. (2025, April 6). Pharma logistics 2025: Navigating tariff turmoil and ensuring cargo integrity. *Sensos*. https://sensos.io/resources/technology-innovation/pharma-logistics-2025-navigating-tariff-turmoil-and-ensuring-cargo-integrity/
- Reuters. (2025, April 25). Exclusive: US pharma tariffs would raise US drug costs by $51 bln annually, report finds. *Reuters*. https://www.reuters.com/business/healthcare-pharmaceuticals/us-pharma-tariffs-would-raise-us-drug-costs-by-51-bln-annually-report-finds-2025-04-25/
- Delve Insight. (2025, May 6). Navigating U.S. tariffs in 2025: Impacts on pharma & healthcare strategies. *Delve Insight Blog*. https://www.delveinsight.com/blog/us-tariffs-2025-impact-healthcare-pharma-strategies
- SG Analytics. (2025, May 12). Supply chain in the pharmaceutical industry - trends. *SG Analytics*. https://www.sganalytics.com/blog/supply-chain-in-pharmaceutical-industry-trends/
- SuperStaff. (2025, May 13). Strengthening the supply chain in pharmaceutical industry. *SuperStaff*. https://www.superstaff.com/blog/prescription-drug-shortages-2025-how-outsourcing-strengthens-the-supply-chain-in-the-pharmaceutical-industry-amid-the-us-trade-war/
- Drug Discovery News. (2025, May 28). Designing for disruption in the pharmaceutical supply chain. *Drug Discovery News*. https://www.drugdiscoverynews.com/designing-for-disruption-in-the-pharmaceutical-supply-chain-16404

ISSN: 3139-3195